Phase 2 Brain Cancer Trial, Recruiting NCT05864534 Sponsor: Northwestern University Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT05864534
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been recently diagnosed with a specific type of brain tumor called glioblastoma, confirmed by a lab test, with a particular genetic profile (called "IDH wild-type")
  • Your tumor has a specific genetic marker called "MGMT unmethylated" (a lab test your doctor can check)
  • A preserved sample of your tumor tissue is available for the study to use
  • You have already finished standard radiation treatment, with or without a chemotherapy drug called temozolomide
  • You are 18 years of age or older
  • You are able to have an MRI scan with contrast dye
  • You are reasonably able to carry out daily activities (your doctor will assess this using a standard scale)
  • The size and location of your tumor or surgery site allows it to be reached by a special sound wave treatment used in this trial
  • You have never previously received any immunotherapy treatments for your brain tumor or any other condition
  • You are able to understand and willing to sign a consent form before joining the study
  • You are willing and able to follow the study's requirements
  • Your liver, kidneys, and blood counts are working well enough (confirm with trial site)
  • You are willing to use appropriate contraception if this applies to you

Who may not be able to join:

  • Your tumor appears in multiple locations in the brain, unless all areas are within a small zone that the sound wave treatment can reach, OR your tumor is located in the lower back part of the brain (called the posterior fossa)
  • You have epilepsy (seizures) that is not well controlled with medication
  • You have taken part in another clinical trial or received an experimental treatment within the last 2 weeks
  • You have previously had a serious allergic reaction to medicines that are similar to those used in this trial
  • You have a medical reason why you cannot receive a type of treatment called a checkpoint inhibitor, such as a history of certain immune system diseases
  • You have a serious illness that is currently not under control
  • You have had another type of cancer (other than your brain tumor) that was active within the past 12 months
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Adam Sonabend, MD, Northwestern University

Phone: (312) 695-8143

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
19 January 2024
Est. completion
31 July 2031

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Unacceptable toxicity rate; Landmark survival analyses

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov